El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) Current Deferred Revenue: E£0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:NIPH El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile CAI:NIPH
28 GF Score
Price E£372.30
! 4 Warning Signs
View Full Analysis

What is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Current Deferred Revenue?

El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile CAI:NIPH +2.00% 28 Current Deferred Revenue is E£0 Mil as of Mar. 2026. GuruFocus rates CAI:NIPH with a GF Score™ of 28/100. The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current deferred revenue for the quarter that ended in Mar. 2026 was E£0 Mil.

El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Current Deferred Revenue Related Terms

El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Current Deferred Revenue Chart

El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Annual Data
Trend Jun24 Jun25
Current Deferred Revenue
0.00 0.00

El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Quarterly Data
Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
CAI:NIPH
28GF Score
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile CAI:NIPH
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of E£0 Mil mean?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a Current Deferred Revenue of E£0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Current Deferred Revenue too high?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Current Deferred Revenue is E£0 Mil. Overall, El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Current Deferred Revenue compare to ZTS and UTHR?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's Current Deferred Revenue of E£0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile and its competitors. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's current Current Deferred Revenue is E£0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile stock overvalued right now?
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH) has a current Current Deferred Revenue of E£0 Mil. The current Current Deferred Revenue is E£0 Mil. El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile (CAI:NIPH), the current Current Deferred Revenue is E£0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile Business Description

Address Al-Sawah square, ElAmeria, Cairo, EGY
El-Nile Co For Pharmaceuticals And Chemical Industries - ElNile manufactures and markets pharmaceuticals, medicinal materials, chemical products and surgical threads and medical solutions.
28GF Score

Get the complete analysis for CAI:NIPH

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£372.30
Price